• Science publication: New data show breakthrough microRNA-targeted therapy developed using proprietary LNA technology holds promise as new treatment for Hepatitis C 
• Closed major new deal with Wyeth, potentially worth in excess of $800m in upfront and milestones
• Closed major new deal with Shire plc, potentially worth in excess of $380m in upfront and milestones
• Strengthened the Company patent estate with 14 new patent applications
• Published >10 scientific papers in key seminal journals including Science, Nature, PNAS
• Established US subsidiary located in San Diego 

• Nature publication: LNA mediated microRNA silencing in non-human primates
• First-in-Man trial with SPC3649 targeting microRNA-122 is initiated
• Danish Advanced Technology Foundation awards Santaris Pharma Consortium DKK45m (€6m) to enhance the discovery of RNA medicines
• Santaris Pharma is named Fierce 15 Company by Fierce Biotech
• Santaris Pharma is nominated finalist for the Scrip Award ‘Biotech Company of the year’
• Santaris Pharma concentrates its own R&D activities on infectious diseases and metabolic disorders
• A global R&D and commercial partnership is established with Wyeth Pharmaceuticals, covering 10 LNA drug candidates (worth $83m in potential milestones per target)
• Enzon Pharmaceuticals files an IND regarding the jointly developed Survivin cancer drug candidate
• By the end of 2008 Santaris Pharma has 4 clinical stage drugs, 11 discovery/pre-clinical stage drugs, and 3 partnerships, covering 22 drugs

• Enzon files an IND regarding 2 Phase I/II US clinical trials testing EZN2968 in advanced cancer,  targeting HIF-1α 
• Successful outcome of initial CLL Phase I/II clinical cancer (SPC2996) targeting Bcl-2 is reported at ASCO
• The Danish Advanced Technology Foundation awards the second €1m grant to Santaris Pharma to support the development of therapeutics targeting microRNAs
• SPC3649, the Company’s first LNA-antimiR®, targeting the liver specific microRNA-122 commences preclinical development
• An LNA compound targeting apolipoprotein B for cholesterol control initiates preclinical development
• The second Phase I/II clinical trial (Part B) of SPC2996 in CLL is completed
• A global R&D and commercial partnership is established with GlaxoSmithKline for up to four programs in viral diseases (worth > $700m in potential milestones)
• €20m Series C investment led by new investor Gilde Healthcare Partners 

2006

• €40m Series B investment by new (Forbion, GLSV, Sunstone, Seventure) and existing investors
• Santaris Pharma and Enzon Pharmaceuticals establish a global partnership in oncology, covering HIF-1α and Survivin compounds as well as six novel cancer targets (worth >$200m in potential milestones)
• Danish Advanced Technology Foundation awards its first ever biotech grant (€1m) to Santaris Pharma to support development of microRNA 
• Strategic focus is expanded to include metabolic disorders
• Santaris Pharma is named Biotech Entrepreneur of the Year by Ernst and Young

• Preclinical development of SPC2968 (targeting HIF-1α ) is commenced
• International Phase I/II clinical study of SPC2996 in CLL targeting BCl-2 is commenced
• Preclinical development of SPC3042 (targeting Survivin) is commenced
• MicroRNA research program is established

2004

• Three drug discovery programs are commenced – targeting Bcl-2, Survivin and HIF-1α
• Preclinical development of SPC2996 (targeting Bcl-2) is commenced

• Santaris Pharma is founded in Copenhagen, Denmark through the merger of Cureon and Pantheco
• € 6m Series A investment from Cureon and Pantheco shareholders (Bankinvest, Novo, LD pensions, InnKap, TechnoInvest and others)